openPR Logo
Press release

Glaucoma Competitive Landscape Report (Updated) | Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, AbbVie, and others.

01-12-2024 12:42 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Glaucoma Competitive Landscape

Glaucoma Competitive Landscape

DelveInsight's, "Glaucoma Competitive Landscape" report provides comprehensive insights about 45+ Glaucoma companies and 50+ drugs in Glaucoma Competitive landscape. It covers the Glaucoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Glaucoma Competitive Landscape Report
• DelveInsight's Glaucoma report depicts a robust space with 45+ Glaucoma companies working to develop 50+ pipeline therapies for Glaucoma treatment.
• The leading Glaucoma Companies working in the market include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, Future Medicine, PolyActiva Pty Ltd, Theratocular Biotek, Whitecap Biosciences, JeniVision, AbbVie, Noveome Biotherapeutics, and others.
• Promising Glaucoma therapies in the various stages of development include rhNGF, Aflibercept (Eylea, BAY 86-5321), OPA-6566, Latanoprost, TO-O-1001, ONL1204 Ophthalmic solution (Dose A), and others.
• December 2023: Laboratorios Sophia S.A de C.V. announced a study of Phase 3 clinical trials for PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic and Krytantek. A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma.

Request a sample and discover the recent advances in Glaucoma Drugs @ Glaucoma Competitive Landscape Report- https://www.delveinsight.com/report-store/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Glaucoma report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Glaucoma report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Glaucoma Overview
Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The "angle" in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

Find out more about Glaucoma Analytical Perspective: In-depth Commercial Assessment @ Glaucoma Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glaucoma Companies and Therapies
• Allergan: DURYSTA
• Sun Pharma Advanced Research Company Limited: XELPROS
• Nicox Ophthalmics: NCX 470
• Tarsier Pharma: TRS01
• Qlaris Bio: QLS-101
• Noveome Biotherapeutics: ST266

Glaucoma Competitive Landscape
The Glaucoma report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Glaucoma Report Assessment
• Company Analysis
• Glaucoma Therapeutic Assessment
• Glaucoma Pipeline Assessment
• Inactive Glaucoma Drugs Assessment
• Glaucoma Unmet Needs

Learn more about the emerging Glaucoma Competitive Landscape @ Glaucoma Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glaucoma Competitive Landscape Report
• Coverage- Global
• Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, Future Medicine, PolyActiva Pty Ltd, Theratocular Biotek, Whitecap Biosciences, JeniVision, AbbVie, Noveome Biotherapeutics, and others.
• Glaucoma therapies- rhNGF, Aflibercept (Eylea, BAY 86-5321), OPA-6566, Latanoprost, TO-O-1001, ONL1204 Ophthalmic solution (Dose A), and others.
• Glaucoma Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

Dive deep into rich insights for new drugs for Glaucoma Product Developmental Activities, Visit @ Glaucoma Research and Development Activities- https://www.delveinsight.com/sample-request/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Glaucoma: Overview
4. Glaucoma -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Glaucoma: Company and Product Profiles (Marketed Therapies)
8. Allergan
9. DURYSTA
10. Glaucoma: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Nicox Ophthalmics
13. NCX 470
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Qlaris Bio
17. QLS-101
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Noveome Biotherapeutics
21. ST266
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Glaucoma- Unmet needs
29. Glaucoma Market drivers and barriers
30. Appendix

For further information on the Glaucoma Report @ Glaucoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links

https://quantummemoir.mn.co/members/21285995
https://rightbusinesspath.mn.co/posts/48636294
https://tennispassion.mn.co/posts/48636354
https://king-business.mn.co/posts/48636411
https://forums.mbclub.co.uk/members/dennydones99.180319/#about
https://www.creativelive.com/student/dennydones1?via=accounts-freeform_2
https://tl.net/forum/profile.php?user=dennydones99
https://minne.com/@dennydones99/profile
https://network-79379.mn.co/members/20103624
https://ylimun.mn.co/members/20103614
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market
https://biomolecula.ru/authors/25303
https://discuss.machform.com/u/dennydones9191
https://dagshub.com/dennydones9191
https://careerkarma.com/profile/clr7d7z0c04v2lf3k5lrx9vyr/
https://gotech.mn.co/posts/48477911
https://landmarknew.mn.co/posts/48477947
https://infiniteabundance.mn.co/posts/48478016
https://wellbeingmatters.mn.co/posts/48478424
https://vrjam.mn.co/posts/48478544
https://decidim.santcugat.cat/profiles/dennydones9/activity
https://haveagood.holiday/users/336105
https://participa.rubi.cat/profiles/dennydones9191/activity
https://forum.callofwar.com/index.php?user/60304-dennydones9191/#about
https://connectgalaxy.com/post/146081_syphilis-a-sexually-transmitted-bacterial-infection-caused-by-treponema-pallidum.html
https://www.thebostoncalendar.com/user/74833
https://wrongplanet.net/author/dennydones9999/
https://bookmark.hiauthors.com/story/syphilis-market
https://www.openhumans.org/member/anniethomas/
https://cynochat.com/read-blog/160375
https://hitrecord.org/users/dennydones9999/records
https://biiut.com/read-blog/918
https://nimmansocial.com/story5840956/syphilis-market
https://bookmarkbirth.com/story15878475/syphilis-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/stem-cell-market

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glaucoma Competitive Landscape Report (Updated) | Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, AbbVie, and others. here

News-ID: 3350647 • Views:

More Releases from DelveInsight Business Research LLP

Tuberous Sclerosis Complex Drug Market 2034: Epidemiology, Latest FDA Approvals | Jazz Pharmaceuticals, Novartis Pharmaceuticals, Nobelpharma, Marinus Pharmaceuticals, GW Pharmaceuticals, Noema Pharma AG, and others.
Tuberous Sclerosis Complex Drug Market 2034: Epidemiology, Latest FDA Approvals …
DelveInsight's "Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Tuberous Sclerosis Complex, historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Tuberous Sclerosis Complex Market • The increase in Tuberous Sclerosis Complex Market Size is a direct consequence of the increasing
Gastroparesis Drug Market Report 2034: Epidemiology, Latest FDA Approvals | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
Gastroparesis Drug Market Report 2034: Epidemiology, Latest FDA Approvals | Vand …
DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Discover which therapies are expected to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Gastroparesis Market Report • The total Gastroparesis prevalent cases in
Geographic Atrophy Drug Market Report 2034: Epidemiology, Latest FDA Approvals | Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis
Geographic Atrophy Drug Market Report 2034: Epidemiology, Latest FDA Approvals | …
DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Discover which therapies are expected to grab the Geographic Atrophy Market Share @ Geographic Atrophy Market Outlook- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Geographic Atrophy Market
Systemic Lupus Erythematosus Drug Market Report 2034: Epidemiology, Latest FDA Approvals | GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma
Systemic Lupus Erythematosus Drug Market Report 2034: Epidemiology, Latest FDA A …
DelveInsight's "Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Discover which therapies are expected to grab the Systemic Lupus Erythematosus market share @ Systemic Lupus Erythematosus Market Outlook Report- https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key

All 5 Releases


More Releases for Glaucoma

Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the
Glaucoma – Epidemiology Insights (2016-2028)
Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1159 The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the
Market Spotlight: Glaucoma
Boston, MA ReportsWorldwide has announced the addition of a new report title Market Spotlight: Glaucoma to its growing collection of premium market research reports. Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which may cause loss of vision and blindness. In glaucoma, damage to the optic nerve is usually caused by elevated intraocular pressure (IOP). IOP rises when passages that allow fluid
North America Glaucoma Therapeutics Market grows with growing awareness regardin …
Glaucoma Therapeutics Market: Scope and Methodology The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study
Glaucoma Treatment Market : Rising Geriatric Population And Healthcare Expenditu …
Glaucoma is a chronic, degenerative, permanent disorder whose rate increases essentially with age rather than causing immediate blindness. According to a survey of WHO, Glaucoma is the second most common cause of blindness affecting the population worldwide after cataract (47.9%). In general, Glaucoma occurs as after effects of increased intraocular pressure (IOP) brought about by an abnormality or malfunctioning of the eye drainage system. The normal IOP is in
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide. Sudden increase in the aging population and